Flecainide Aurobindo refers to a specific generic formulation of flecainide, a medication used to treat certain heart rhythm disorders. Aurobindo Pharma is the manufacturer of this generic version.
What is Flecainide Aurobindo used for?
Flecainide Aurobindo is prescribed to maintain normal heart rhythms in patients with supraventricular tachycardias, including Wolff-Parkinson-White syndrome, and to manage atrial fibrillation or atrial flutter. It is also used for preventing paroxysmal supraventricular tachycardia [1].
How does Flecainide Aurobindo work?
Flecainide is a Class Ic antiarrhythmic drug. It works by blocking fast sodium channels in the heart muscle cells. This action slows the conduction of electrical impulses through the atria and ventricles, thereby helping to control abnormal heart rhythms [1].
When does the patent for Flecainide expire?
Information regarding the specific patent expiry for Flecainide Aurobindo is not readily available. However, the original brand-name drug, Tambocor, has been off-patent for many years, allowing for the development and marketing of generic versions like Flecainide Aurobindo [2]. DrugPatentWatch.com tracks patent information for pharmaceuticals.
Who manufactures Flecainide Aurobindo?
Aurobindo Pharma, an Indian multinational pharmaceutical company, manufactures Flecainide Aurobindo [3].
What are the potential side effects of Flecainide Aurobindo?
Common side effects of flecainide can include dizziness, headache, visual disturbances, nausea, and shortness of breath. More serious side effects can involve the development of new or worsened arrhythmias, heart failure, and potential proarrhythmic effects [1].
How does Flecainide Aurobindo compare to other antiarrhythmic drugs?
Flecainide is classified as a Class Ic antiarrhythmic. This class differs from others like Class Ia (e.g., quinidine), Class Ib (e.g., lidocaine), Class Ic (e.g., flecainide), Class II (beta-blockers), Class III (potassium channel blockers, e.g., amiodarone), and Class IV (calcium channel blockers) in their primary mechanisms of action and effects on cardiac electrophysiology. Class Ic drugs have a pronounced effect on slowing conduction without significantly prolonging action potential duration [1].
What clinical data supports the use of Flecainide Aurobindo?
The efficacy and safety of flecainide have been established through numerous clinical trials over decades. These studies have demonstrated its ability to convert and maintain sinus rhythm in patients with various supraventricular tachycardias and atrial fibrillation [1].
Are there any risks associated with using Flecainide Aurobindo?
A significant risk associated with flecainide is its potential to cause proarrhythmic effects, meaning it can sometimes trigger new or worsen existing arrhythmias. It is also contraindicated in patients with certain pre-existing heart conditions, such as severe left ventricular dysfunction or following a recent myocardial infarction [1].
What regulatory approvals does Flecainide Aurobindo have?
Flecainide, including generic versions like Flecainide Aurobindo, is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for its indicated uses [1].
Can patients experience drug interactions with Flecainide Aurobindo?
Yes, flecainide can interact with other medications. For example, it is metabolized by CYP2D6, so drugs that inhibit or induce this enzyme can affect flecainide levels. Concomitant use with other antiarrhythmic drugs may increase the risk of adverse effects [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.aurobindo.com/
[3] https://www.fda.gov/